Mariya Salman

828 total citations
12 papers, 91 citations indexed

About

Mariya Salman is a scholar working on Genetics, Pathology and Forensic Medicine and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Mariya Salman has authored 12 papers receiving a total of 91 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Genetics, 10 papers in Pathology and Forensic Medicine and 3 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Mariya Salman's work include Chronic Lymphocytic Leukemia Research (12 papers), Lymphoma Diagnosis and Treatment (10 papers) and Acute Lymphoblastic Leukemia research (3 papers). Mariya Salman is often cited by papers focused on Chronic Lymphocytic Leukemia Research (12 papers), Lymphoma Diagnosis and Treatment (10 papers) and Acute Lymphoblastic Leukemia research (3 papers). Mariya Salman collaborates with scholars based in United Kingdom, United States and France. Mariya Salman's co-authors include Angela Howes, Michelle Mahler, Asher Chanan‐Khan, Steven Sun, Graeme Fraser, Simon Rule, Michael Hallek, Paula Cramer, Sebastian Grosicki and Sen Hong Zhuang and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Pharmaceutical Research.

In The Last Decade

Mariya Salman

12 papers receiving 91 citations

Peers

Mariya Salman

GENET

PFM

HEMAT

IMMUN

PRM

Tommi Salmi United States

M Asuncion Echeveste Spain

Kara Higgins United States

Ganna Usenko Ukraine

Iryna Kriachok Ukraine

S. Stilgenbauer Germany

Éric Durot France

Marina Deodato Italy

Mona Stefanos United States

Elżbieta Iskierka‐Jazdzewska Poland

Tommi Salmi United States

Mariya Salman

86 ×1.0

GENET

75 ×0.9

PFM

24 ×0.7

HEMAT

23 ×1.6

IMMUN

8 ×0.7

PRM

Citations per year, relative to Mariya Salman Mariya Salman (= 1×) peers Tommi Salmi

Countries citing papers authored by Mariya Salman

Since Specialization

Citations

This map shows the geographic impact of Mariya Salman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mariya Salman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mariya Salman more than expected).

Fields of papers citing papers by Mariya Salman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mariya Salman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mariya Salman. The network helps show where Mariya Salman may publish in the future.

Co-authorship network of co-authors of Mariya Salman

This figure shows the co-authorship network connecting the top 25 collaborators of Mariya Salman. A scholar is included among the top collaborators of Mariya Salman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mariya Salman. Mariya Salman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

1.

Jong, Jan de, Paula Cramer, Fatih Demırkan, et al.. (2019). Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial. Pharmaceutical Research. 36(7). 93–93. 3 indexed citations

2.

Beishuizen, Auke, Deepa Bhojwani, Birgit Burkhardt, et al.. (2019). IBRUTINIB + CHEMOIMMUNOTHERAPY (CIT) FOR RELAPSED/REFRACTORY MATURE B‐CELL NON‐HODGKIN LYMPHOMA (B‐NHL) IN CHILDREN (SPARKLE TRIAL): INITIAL SAFETY, PK, AND EFFICACY. Hematological Oncology. 37(S2). 57–59. 2 indexed citations

3.

Cramer, Paula, Graeme Fraser, Sebastian Grosicki, et al.. (2018). Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in the HELIOS study. Leukemia & lymphoma. 59(9). 2075–2084. 13 indexed citations

4.

Cramer, Paula, Fatih Demırkan, Graeme Fraser, et al.. (2017). IBRUTINIB INCREASES THE SYSTEMIC EXPOSURE OF RITUXIMAB: PHARMACOKINETIC RESULTS FROM THE HELIOS TRIAL. Hematological Oncology. 35(S2). 232–233. 1 indexed citations

5.

Fraser, Graeme, Paula Cramer, Fatih Demırkan, et al.. (2016). IBRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): 2-YEAR FOLLOW-UP INCLUDING MRD FROM THE HELIOS STUDY. Haematologica. 101. 150–151. 4 indexed citations

6.

Fraser, Graeme, Paula Cramer, Fatih Demırkan, et al.. (2016). Ibrutinib (I) plus bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): a 2-year follow-up of the HELIOS study.. Journal of Clinical Oncology. 34(15_suppl). 7525–7525. 8 indexed citations

7.

Cramer, Paula, Fatih Demırkan, Graeme Fraser, et al.. (2016). Systemic Exposure of Rituximab Increased By Ibrutinib: Pharmacokinetic Results from the Helios Trial. Blood. 128(22). 4403–4403. 1 indexed citations

8.

Damle, Rajendra N., Michael Schäffer, Shalini Chaturvedi, et al.. (2016). Early Changes in Circulating T-Cell Immune Profiles in Patients with Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Data from the Phase 3, Double-Blind HELIOS Trial. Blood. 128(22). 4397–4397. 2 indexed citations

9.

Hillmen, Peter, Graeme Fraser, Jeffrey A. Jones, et al.. (2015). Comparing Single-Agent Ibrutinib, Bendamustine Plus Rituximab (BR) and Ibrutinib Plus BR in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): An Indirect Comparison of the RESONATE and HELIOS Trials. Blood. 126(23). 2944–2944. 20 indexed citations

10.

Chanan‐Khan, Asher, Paula Cramer, Fatih Demırkan, et al.. (2015). Ibrutinib combined with bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): First results from a randomized, double-blind, placebo-controlled, phase III study.. Journal of Clinical Oncology. 33(15_suppl). LBA7005–LBA7005. 3 indexed citations

11.

Chanan‐Khan, Asher, Paula Cramer, Fatih Demırkan, et al.. (2015). Ibrutinib combined with bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): First results from a randomized, double-blind, placebo-controlled, phase III study.. Journal of Clinical Oncology. 33(18_suppl). LBA7005–LBA7005. 15 indexed citations

12.

Hallek, Michael, Neil E. Kay, Anders Österborg, et al.. (2014). The HELIOS Trial Protocol: A Phase III Study of Ibrutinib in Combination with Bendamustine and Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia. Future Oncology. 11(1). 51–59. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact